Ligand Pharmaceuticals Incorporated (FRA:LGDN)

Germany flag Germany · Delayed Price · Currency is EUR
160.00
+4.00 (2.56%)
At close: Jan 30, 2026
42.86%
Market Cap3.18B +57.1%
Revenue (ttm)214.13M +64.8%
Net Income41.41M +7.4%
EPS2.12 +0.8%
Shares Outn/a
PE Ratio76.86
Forward PE23.30
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume6
Open161.00
Previous Close156.00
Day's Range160.00 - 161.00
52-Week Range86.00 - 181.00
Betan/a
RSI46.21
Earnings DateFeb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 68
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LGDN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements